Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study
Article in Thoracic Cancer (January 2023)
The most recent citing publications are shown below. View all 37 publications that cite this research output on Dimensions.
Modified Eligibility Criteria: Patient Access and Subpopulation Applicability vs Efficiency in Drug Development
Article in Journal of the National Cancer Institute (September 2022)
Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors
Article in Frontiers in Oncology (August 2022)